These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 21359109)

  • 21. Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors.
    Knudsen HK; Ducharme LJ; Roman PM
    J Subst Abuse Treat; 2006 Jun; 30(4):363-73. PubMed ID: 16716852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment and treatment of co-occurring eating disorders in privately funded addiction treatment programs.
    Killeen TK; Greenfield SF; Bride BE; Cohen L; Gordon SM; Roman PM
    Am J Addict; 2011; 20(3):205-11. PubMed ID: 21477048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Barriers to the implementation of medication-assisted treatment for substance use disorders: the importance of funding policies and medical infrastructure.
    Knudsen HK; Abraham AJ; Oser CB
    Eval Program Plann; 2011 Nov; 34(4):375-81. PubMed ID: 21371752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adoption of medications in substance abuse treatment: priorities and strategies of single state authorities.
    Rieckmann T; Kovas AE; Rutkowski BA
    J Psychoactive Drugs; 2010 Sep; Suppl 6():227-38. PubMed ID: 21138199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The adoption of alcohol pharmacotherapies in the Clinical Trials Network: the influence of research network participation.
    Abraham AJ; Knudsen HK; Rothrauff TC; Roman PM
    J Subst Abuse Treat; 2010 Apr; 38(3):275-83. PubMed ID: 20117908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacotherapy of alcohol use disorders and concurrent psychiatric disorders: a review.
    Lev-Ran S; Balchand K; Lefebvre L; Araki KF; Le Foll B
    Can J Psychiatry; 2012 Jun; 57(6):342-9. PubMed ID: 22682571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improving the quality of substance dependency treatment with pharmacotherapy.
    Boyarsky BK; McCance-Katz EF
    Subst Use Misuse; 2000; 35(12-14):2095-125. PubMed ID: 11138718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network.
    Knudsen HK; Abraham AJ; Johnson JA; Roman PM
    J Subst Abuse Treat; 2009 Oct; 37(3):307-12. PubMed ID: 19577406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Innovative perspectives on strategies to develop effective alcoholism treatment programs.
    Drug Alcohol Depend; 1995 Sep; 39 Suppl 1():S23-4. PubMed ID: 8565794
    [No Abstract]   [Full Text] [Related]  

  • 30. Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.
    Stein BD; Pacula RL; Gordon AJ; Burns RM; Leslie DL; Sorbero MJ; Bauhoff S; Mandell TW; Dick AW
    Milbank Q; 2015 Sep; 93(3):561-83. PubMed ID: 26350930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Challenges and Opportunities for the Use of Medications to Treat Opioid Addiction in the United States and Other Nations of the World.
    Parrino MW; Maremmani AG; Samuels PN; Maremmani I
    J Addict Dis; 2015; 34(2-3):255-62. PubMed ID: 26110357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.
    DeFlavio JR; Rolin SA; Nordstrom BR; Kazal LA
    Rural Remote Health; 2015; 15():3019. PubMed ID: 25651434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of program services on treatment outcomes of patients with comorbid mental and substance use disorders.
    Grella CE; Stein JA
    Psychiatr Serv; 2006 Jul; 57(7):1007-15. PubMed ID: 16816286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. For what diagnoses are psychotropic medications being prescribed?: a nationally representative survey of physicians.
    Mark TL
    CNS Drugs; 2010 Apr; 24(4):319-26. PubMed ID: 20297856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prevalence of mental and physical health disorders among older methadone patients.
    Rosen D; Smith ML; Reynolds CF
    Am J Geriatr Psychiatry; 2008 Jun; 16(6):488-97. PubMed ID: 18515693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs.
    Friedmann PD; Jiang L; Alexander JA
    J Behav Health Serv Res; 2010 Jul; 37(3):322-37. PubMed ID: 19296223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prevalence of psychiatric disorders in French general practice using the patient health questionnaire: comparison with GP case-recognition and psychotropic medication prescription].
    Norton J; de Roquefeuil G; David M; Boulenger JP; Ritchie K; Mann A
    Encephale; 2009 Dec; 35(6):560-9. PubMed ID: 20004287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Organizational capacity to address co-occurring substance use and psychiatric disorders: assessing variation by level of care.
    Lambert-Harris C; Saunders EC; McGovern MP; Xie H
    J Addict Med; 2013; 7(1):25-32. PubMed ID: 23188042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current status of co-occurring mood and substance use disorders: a new therapeutic target.
    Pettinati HM; O'Brien CP; Dundon WD
    Am J Psychiatry; 2013 Jan; 170(1):23-30. PubMed ID: 23223834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Substance abuse treatment organizations as mediators of social policy: slowing the adoption of a congressionally approved medication.
    Wallack SS; Thomas CP; Martin TC; Chilingerian J; Reif S
    J Behav Health Serv Res; 2010 Jan; 37(1):64-78. PubMed ID: 18668369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.